-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Head to Head Analysis: Akili (NASDAQ:AKLI) and Femasys (NASDAQ:FEMY)
Head to Head Analysis: Akili (NASDAQ:AKLI) and Femasys (NASDAQ:FEMY)
Femasys (NASDAQ:FEMY – Get Rating) and Akili (NASDAQ:AKLI – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations and institutional ownership.
Profitability
This table compares Femasys and Akili's net margins, return on equity and return on assets.
Get Femasys alerts:Net Margins | Return on Equity | Return on Assets | |
Femasys | -886.22% | -48.96% | -44.68% |
Akili | N/A | -53.80% | -5.15% |
Analyst Recommendations
This is a summary of current recommendations and price targets for Femasys and Akili, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Femasys | 0 | 0 | 3 | 0 | 3.00 |
Akili | 0 | 1 | 4 | 0 | 2.80 |
Insider & Institutional Ownership
7.5% of Femasys shares are held by institutional investors. Comparatively, 78.0% of Akili shares are held by institutional investors. 20.8% of Femasys shares are held by company insiders. Comparatively, 20.4% of Akili shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares Femasys and Akili's top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Femasys | $1.18 million | 9.31 | -$7.54 million | ($0.79) | -1.18 |
Akili | N/A | N/A | -$2.44 million | N/A | N/A |
Akili has lower revenue, but higher earnings than Femasys.
Volatility & Risk
Femasys has a beta of -0.31, indicating that its stock price is 131% less volatile than the S&P 500. Comparatively, Akili has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500.
Summary
Akili beats Femasys on 6 of the 11 factors compared between the two stocks.
About Femasys
(Get Rating)
Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.
About Akili
(Get Rating)
Akili, Inc., a digital medicine company, develops digital therapeutics for cognitive impairments. It provides EndeavorRx, a physician-prescribed video game-based treatment designed to directly target cognitive functioning. The company is based in Boston, Massachusetts.
Receive News & Ratings for Femasys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Femasys and related companies with MarketBeat.com's FREE daily email newsletter.
Femasys (NASDAQ:FEMY – Get Rating) and Akili (NASDAQ:AKLI – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations and institutional ownership.
費瑪斯(納斯達克:Femy-Get評級)和阿基利(納斯達克:Akli-Get評級)都是小盤醫療公司,但哪隻股票更好?我們將根據這兩家公司的風險、估值、收益、盈利能力、股息、分析師建議和機構所有權等方面的實力進行比較。
Profitability
盈利能力
This table compares Femasys and Akili's net margins, return on equity and return on assets.
此表比較了Femasys和Akii的淨利潤率、股本回報率和資產回報率。
Net Margins | Return on Equity | Return on Assets | |
Femasys | -886.22% | -48.96% | -44.68% |
Akili | N/A | -53.80% | -5.15% |
淨利潤率 | 股本回報率 | 資產回報率 | |
費馬西斯 | -886.22% | -48.96% | -44.68% |
阿基裡 | 不適用 | -53.80% | -5.15% |
Analyst Recommendations
分析師建議
This is a summary of current recommendations and price targets for Femasys and Akili, as provided by MarketBeat.com.
這是MarketBeat.com提供的對Femasys和Akii的當前建議和目標價的摘要。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Femasys | 0 | 0 | 3 | 0 | 3.00 |
Akili | 0 | 1 | 4 | 0 | 2.80 |
銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
費馬西斯 | 0 | 0 | 3 | 0 | 3.00 |
阿基裡 | 0 | 1 | 4 | 0 | 2.80 |
Insider & Institutional Ownership
內部人與機構所有權
7.5% of Femasys shares are held by institutional investors. Comparatively, 78.0% of Akili shares are held by institutional investors. 20.8% of Femasys shares are held by company insiders. Comparatively, 20.4% of Akili shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Femasys 7.5%的股份由機構投資者持有。相比之下,Akii 78.0%的股票由機構投資者持有。Femasys 20.8%的股份由公司內部人士持有。相比之下,Akii 20.4%的股份由公司內部人士持有。強大的機構持股表明,對沖基金、大型基金管理公司和捐贈基金相信,一隻股票有望實現長期增長。
Valuation and Earnings
估值和收益
This table compares Femasys and Akili's top-line revenue, earnings per share (EPS) and valuation.
該表格比較了Femasys和Akii的營收、每股收益(EPS)和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Femasys | $1.18 million | 9.31 | -$7.54 million | ($0.79) | -1.18 |
Akili | N/A | N/A | -$2.44 million | N/A | N/A |
總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 本益比 | |
費馬西斯 | 118萬美元 | 9.31 | -754萬元 | ($0.79) | -1.18 |
阿基裡 | 不適用 | 不適用 | -244萬元 | 不適用 | 不適用 |
Akili has lower revenue, but higher earnings than Femasys.
Akii的收入低於Femasys,但收入高於Femasys。
Volatility & Risk
波動性與風險
Femasys has a beta of -0.31, indicating that its stock price is 131% less volatile than the S&P 500. Comparatively, Akili has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500.
Femasys的貝塔係數為-0.31,表明其股價的波動性比標準普爾500指數低131%。相比之下,Akii的貝塔係數為0.79,這表明其股價的波動性比標準普爾500指數低21%。
Summary
摘要
Akili beats Femasys on 6 of the 11 factors compared between the two stocks.
在比較兩只股票的11個因素中,Akii有6個超過了Femasys。
About Femasys
關於Femasys
(Get Rating)
(獲取評級)
Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.
生物醫藥公司Femasys Inc.專注於美國的女性保健市場。該公司開發了永久性節育解決方案,如FemBloc和FemChec;FemaSeed,一種人工授精解決方案;FemCerv,一種用於宮頸刮宮的活檢設備;以及FemEMB,一種用於子宮內膜採樣以支持子宮癌檢測測試的候選產品。它還在美國、歐洲、加拿大、日本和國際上將FemVue鹽分空氣設備商業化。該公司向婦科醫生、相關的醫療保健專業人員、女性保健提供者組織和生殖內分泌學家提供不孕不育產品。此外,它還提供非手術產品技術。Femasys Inc.成立於2004年,總部設在佐治亞州的蘇瓦尼。
About Akili
關於阿基利
(Get Rating)
(獲取評級)
Akili, Inc., a digital medicine company, develops digital therapeutics for cognitive impairments. It provides EndeavorRx, a physician-prescribed video game-based treatment designed to directly target cognitive functioning. The company is based in Boston, Massachusetts.
Akii,Inc.是一家數位醫藥公司,開發用於認知障礙的數位療法。它提供EndeavorRx,這是一種醫生開出的基於視頻遊戲的治療方法,旨在直接針對認知功能。該公司總部設在馬薩諸塞州波士頓。
Receive News & Ratings for Femasys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Femasys and related companies with MarketBeat.com's FREE daily email newsletter.
接受Femasys Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Femasys和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧